Vaccination increases antibodies on the nose as the first barrier against coronavirus.

Great difference between the Pfizer and AstraZeneca vaccines.

Ghent, September 15, 2021 – Uz Gent and Vib researchers (Flamenco Institute for Biotechnology) have studied the production of covid-19 antibodies on the nose. 78.3% of the participants of the study built antibodies on that site after vaccination. The antibodies in the nose can be an important brake in the infection and propagation.

Antibodies as protection against COVID-19.


“The coronavirus enters our body through the upper respiratory tract,” explains the nose, the throat and the specialist teacher in the ear. Dr. Philippe Gevaert. “Neutralizing antibodies in our blood cause the virus harmless when blocking the binding of tip proteins to human cells. If the antibodies are also present in the nose, they can already form a first barrier there against the entry of the virus. Therefore, it is also important to also investigate the reaction to an infection and vaccination in the nose.

Most nose antibodies after the Vaccination of Pfizer


Blood and nose were examined twice in 46 study participants: just before the first vaccination with Pfizer or AstraZeneca and 13 to 40 days after the second vaccination. 23 The participants had an infection before their vaccination. Just before its first vaccination, only 17.4% of them showed antibodies on the nose. After total vaccination, 78.3% of all participants built antibodies on the nose.

The participants who received Pfizer showed more antibodies (96%) than the participants who received AstraZeneca (59%). In addition, local antibodies in Pfizer showed a stronger neutralization of viral spike protein than in AstraZeneca. A last infection of Covid-19 had no influence on the results. The analysis of the blood showed the same amount of antibodies in both vaccination groups.

Continuation of the study.


It is still not clear why some vaccines generate antibodies in the nose more often than others. “The explanation may be due to a different period of time between the two doses or a different effect of vaccines,” he suspects that infectious disease of Dr. Lino Vandekerckhove’s disease teacher. “During a follow-up study, we will assume the additional evolution of the response of the antibody in the blood and nose. We hope to gain more clarity in this way.”